Eli Lilly announced record-breaking weight loss results for its experimental drug retatrutide in late-stage clinical trials, demonstrating its potential as a leading treatment for obesity and Type 2 diabetes. The drug, which targets three hormone pathways involved in appetite and blood sugar regulation, enabled participants to lose up to 25% of their body weight over 80 weeks, according to trial data published Tuesday in The Lancet.
Key findings from the TRIUMPH-2 trial included:
- Participants with Type 2 diabetes and obesity lost an average of 23% of their body weight (approximately 60 pounds) on the highest dose of retatrutide.
- More than half of participants’ body mass index (BMI) dropped below 30, the threshold for obesity, by the trial’s conclusion.
- The drug outperformed existing GLP-1 medications, which typically result in 10–15% weight loss in similar patient groups.
Immediate Impact and Regulatory Status
Retatrutide is not yet approved for use outside of clinical trials. Eli Lilly has indicated plans to submit the drug for regulatory review in the coming months, though no specific timeline for approval has been confirmed. If authorized, it could become the most effective weight-loss medication available, surpassing current options like Mounjaro (tirzepatide) and Wegovy (semaglutide).
How Retatrutide Works
Unlike existing GLP-1 drugs, which target one or two hormone pathways, retatrutide is a triple agonist, simultaneously mimicking GLP-1, GIP, and glucagon. This multi-target approach is designed to:
- Suppress appetite more effectively by acting on amylin and other satiety signals.
- Improve blood sugar control in patients with Type 2 diabetes.
- Accelerate metabolism, leading to greater fat reduction.
Trial participants received weekly injections of retatrutide in varying doses (4mg, 9mg, or 12mg) over 80 weeks. The 12mg dose yielded the highest weight loss, with some patients losing up to 30% of their body weight over 104 weeks in a separate study.
Comparison to Existing Treatments
Current leading weight-loss drugs have shown modest results for patients with Type 2 diabetes:
- Semaglutide (Wegovy): Up to 10% weight loss (21 pounds) in trials.
- Tirzepatide (Mounjaro/Zepbound): Up to 15% weight loss (34 pounds) in trials.
- Retatrutide: Up to 25% weight loss (60 pounds) in the same patient population.
Experts note that retatrutide’s performance rivals bariatric surgery in terms of weight reduction without the need for invasive procedures. Dr. Susan Spratt, an endocrinologist at Duke Health, called the results a “true advance in diabetes care”, highlighting the drug’s potential to address a major unmet need.
Broader Implications for Obesity and Diabetes Treatment
The trial results suggest retatrutide could transform obesity management, particularly for patients with Type 2 diabetes who often struggle to lose weight with existing medications. Obesity-related conditions, including heart disease and osteoarthritis, may also see benefits from the drug’s effects on blood pressure and cholesterol.
Eli Lilly is also testing retatrutide in non-diabetic patients with obesity, with early data showing up to 25% weight loss after 80 weeks and 30% in severe obesity cases after 104 weeks. These findings could expand the drug’s potential market significantly.
Next Steps and Market Potential
Eli Lilly plans to initiate Phase 3 trials for retatrutide by the end of 2024, with regulatory submissions expected to follow. If approved, the drug could compete directly with Mounjaro and Wegovy, which generated $10 billion in combined sales in 2023.
Analysts predict retatrutide could become a blockbuster drug, potentially reaching $15–20 billion in annual sales if it secures widespread adoption. The company has not yet announced pricing or accessibility plans, though industry observers anticipate it may be positioned as a premium-priced treatment given its advanced mechanism.
Patient and Clinical Perspectives
For patients like those in the trial—many of whom had lived with obesity for decades and diabetes for five or more years—the results offer newfound hope. One participant, who lost 85 pounds over 104 weeks, described the drug as a “game changer” for managing both weight and blood sugar.
Clinicians emphasize that while retatrutide shows unprecedented efficacy, long-term safety and side effects remain under review. Common side effects reported in trials include nausea, diarrhea, and constipation, though these were generally mild to moderate in severity.
Industry and Competitive Landscape
Retatrutide’s success could disrupt the weight-loss drug market, where competitors like Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) currently dominate. The drug’s triple-hormone mechanism sets it apart, addressing gaps in appetite suppression that single- or dual-agonist drugs have struggled to fill.
Eli Lilly’s earlier announcement of a combination therapy (eloralintide + tirzepatide) also underscores the company’s aggressive push into obesity treatment. That regimen, currently in Phase 2 trials, showed 23.3% weight loss in participants, further solidifying Lilly’s pipeline dominance in this space.